Drug Overview: Jevtana

  • ID: 4462236
  • Drug Pipelines
  • 16 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen. By promoting tubulin assembly into microtubules while simultaneously preventing disassembly, Jevtana inhibits mitotic and interphase cellular functions, non-specifically inhibiting cell replication.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Jevtana: Prostate cancer

List of Figures
Figure 1: Jevtana for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Jevtana for prostate cancer
Figure 3: Drug assessment summary of Jevtana for prostate cancer
Figure 4: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Jevtana drug profile
Table 2: Jevtana pivotal Phase III data in prostate cancer
Table 3: Jevtana Phase III data in prostate cancer
Table 4: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll